Third IDS - April 15, 2008

				Complete if Known		
				Application Number	10/790,488	
INFORMATION DISCLOSURE				Filing Date	March 1, 2004	
STATEMENT BY APPLICANT			APPLICANT	First Named Inventor	Matthew L. Sherman	
				Art Unit	1617	
(Use as many sheets as necessary)				Examiner Name	Betton, Timothy E.	
Sheet	1	of	1	Attorney Docket Number	AM-101314USA	\neg

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), dete, page(s), volume-issue number(s), publisher, city and/or country where published	T ²			
/T.B./	L41	S. JOHNSTON, ET AL., Integration of Signal Transduction Inhibitors with Endocrine Therapy: An Approach to Overcoming Hormone Resistance in Breast Cancer, Clinical Cancer Research, January 2003 (Suppl.), pp. 524s-532s, vol. 9, presented at the Second International Conference on Recent Advances and Future Directions in Endocrine				
/T.B./	L42	Manipulation of Breast Cancer, June 28-29, 2002 (Cambridge, MA). S. COME, ET AL., Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: Summary Consensus Statement, January 2003 (Suppl.), pp. 443s-446s, vol. 9, summarizing the Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer, June 28-29, 2002 (Cambridge, MA).				

Examiner Signature	/Timothy	/ Betton/	Date Considered	05/08/2008
* EXAMINER: Ini	itial if reference considered, whether or not	citation is in conformance w	rith MPEP 609. Draw line	through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (potional). *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application. Confiderability is governed by 38 USE. 122 and 37 CFR 1.14. This collection is estimated to 4 bours to complete, including gathering, preparing, and submitting the completed application form to the USFTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burder, should be sent to the Chief Information Officer. U.S. Patent and Trademark Diffice, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Va 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissions for Patents, P.O. Box 1459, Alexandria, Va 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.